3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gynecologic
1
Gastrointestinal
1
Breast
1
Conditions
Ovarian Neoplasms
1
Colonic Neoplasms
1
Breast Neoplasms
1
Interventions
Oxaliplatin
16
Irinotecan
12
Fluorouracil
12
Leucovorin
10
Bevacizumab
8
pembrolizumab
7
Cetuximab
7
Capecitabine
7
Nivolumab
5
Gemcitabine
5
Cyclophosphamide
5
fludarabine
4
aldesleukin
4
Panitumumab
4
Folfox protocol
4
oblimersen
3
Interleukin-2
3
selpercatinib
2
poly ICLC
2
labetuzumab
2
dehydroftorafur
2
conatumumab
2
cemiplimab
2
bintrafusp alfa protein, human
2
Tomography, X-Ray Computed
2
Specimen Handling
2
Receptor Protein-Tyrosine Kinases
2
Radiotherapy
2
Levoleucovorin
2
Injections
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 1/2
×
Colonic Neoplasms
×
Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization
×
Clear all
NCT00574678
2021-08-05
ACT
University of Arkansas
Phase 1/2
Completed
150 enrolled